Ipilimumab Versus Placebo After Complete Resection of Stage

Ipilimumab Versus Placebo After Complete Resection of Stage III Melanoma: Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 2 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 3 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Immune Checkpoint Inhibitor Ipilimumab Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

EORTC 18071/CA 184 -029: Study Design Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Key Eligibility Criteria Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 7 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Baseline Patient Characteristics Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Primary Endpoint: Recurrence-free Survival (IRC) Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Recurrence-free Survival: Prespecified Subgroups Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 11 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 12 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Time to Onset of Grade 2 -5 ir. AEs Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 14 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Slide 15 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Subgroup Analyses of RFS: Microscopic (N 1) vs Clinically Palpable (N 2) Lymph Nodes Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Summary/Conclusions Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Acknowledgments Presented By Alexander Eggermont at 2014 ASCO Annual Meeting